Reported figures and Equlion model projections for the next 5 years.
Metric
2025 (actual)
2026
2027
2028
2029
2030
Trend
ROE
157.36%
157.45%
63.13%
43.19%
32.6%
25.82%
ROA
-54.3%
-74.44%
-190.31%
-679.71%
-822.42%
-953.85%
Gross Margin
62.4%
62.4%
62.4%
62.4%
62.4%
62.4%
Sector average
16.85%
17.71%
17.71%
17.71%
17.71%
17.71%
Net Margin
-240.31%
-228.15%
-217.07%
-219.22%
-216.05%
Amounts in SEK (millions); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Stock price and valuation carry no data date: they are the Equlion model's estimate for 2025. Projections are model estimates, not investment advice.
Want the full financial forecast report for Hansa Biopharma AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
-214.34%
Total Assets
SEK 1,166.77M
SEK 602.89M
SEK 121.93M
SEK 111.05M
SEK 100.08M
SEK 92.50M
Sector average
SEK 2,857.19M
SEK 2,900.24M
SEK 3,045.01M
SEK 3,280.29M
SEK 3,536.41M
SEK 3,762.91M
Net Income
-SEK 534.11M
-SEK 658.68M
-SEK 689.71M
-SEK 791.79M
-SEK 868.18M
-SEK 918.47M
Sector average
-SEK 2.85M
-SEK 22.03M
-SEK 0.90M
-SEK 7.25M
-SEK 3.86M
-SEK 1.55M
Valuation
SEK 3,426.86M
SEK 4,226.10M
SEK 4,425.22M
SEK 5,080.12M
SEK 5,570.26M
SEK 5,892.95M
Sector average
SEK 3,960.50M
SEK 5,151.30M
SEK 5,189.24M
SEK 5,317.34M
SEK 5,514.33M
SEK 5,636.78M
Stock Price
SEK 34.36
SEK 42.37
SEK 44.37
SEK 50.94
SEK 55.85
SEK 59.09
Sector average
SEK 57.22
SEK 48.04
SEK 48.69
SEK 50.45
SEK 52.13
SEK 53.41
Hansa Biopharma AB (publ) (HNSA.ST) Financial Forecast | Equlion
